Lanreotide Acetate

醋酸兰瑞肽

Report date: 2026/04/24 20:01:59

Base Information

Drug NameLanreotide Acetate
Drug Alias Name兰瑞肽醋酸盐Angiopeptin兰瑞肽lanreotidaLanreotide Autogel +[26] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionSomatostatin receptor 5 agonists
TargetsSomatostatin receptor 5
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Gastrointestinal motility disordersGastroenteropancreatic neuroendocrine tumor +[24] 
Global Approved IndicationsAcromegalyPituitary NeoplasmsMalignant Carcinoid Syndrome
Approved Indications in ChinaAcromegalyMalignant Carcinoid Syndrome
Original Approved Country/TerritoryN/A
Original Approved Date1994/01/01
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesIpsenBeaufour-Ipsen (Tianjin) Pharmaceutical Co LtdIpsen Pharma Biotech Sas +[6] 
Inactive CompaniesRadboud University Medical CenterUniversity Medical Center GroningenShanghai Jiao Tong University School of Medicine +[8] 
Active IndicationsPancreatic neuroendocrine tumors (pNET)Gastroenteropancreatic neuroendocrine tumorAcromegaly +[7] 
Inactive IndicationsGastrointestinal motility disordersDiarrheaPolycystic Kidney, Autosomal Dominant +[17] 

Other Information

ATC CodeH01CB03
Related LinksWikipediaDrugBankKEGG